STL Index for: Ruxolitinib
Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications
Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.
The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.
The class of medications known as Janus kinase inhibitors block cytokine-mediated signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which plays an important role in immunoregulation and normal cell growth.
While biologics changed the way psoriasis is treated by providing effective targeted therapy, they are not without limitations. Small molecules are emerging therapeutic options for the treatment of psoriasis.